Eli Lilly has revealed that subjects with moderately to severely active Crohn's disease have achieved long-term clinical and endoscopic outcomes after two years of continuous treatment with Omvoh ...

Eli Lilly and Company announced results from the VIVID-2 open-label extension study, which showed the majority of patients with moderately to severely active Crohn's disease receiving two years of ...

Eli Lilly has claimed FDA approval for its IL-23 inhibitor Omvoh as a treatment for moderately to severely active Crohn's disease, extending its use beyond ulcerative colitis (UC) for the first time.

In January the company announced that the US Food and Drug Administration had approved Omvoh for the treatment of moderately to severely active Crohn’s disease in adults. Omvoh is the first ...

The Trump administration is preparing a new executive order that would seek thousands of layoffs at federal health agencies, including the FDA, according to the Wall Street Journal. Citing people ...

In January the company announced that the US Food and Drug Administration had approved Omvoh for the treatment of moderately to severely active Crohn’s disease in adults. Omvoh is the first ...

An antibiotic used to treat infective diarrhea could be an effective drug for a type of inflammatory bowel disease, a new study has found. This study, conducted by researchers from the University ...

We recently compiled a list of the 11 Best Stocks To Invest In For Grandchildren. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other ...

We recently compiled a list of the 11 Best Stocks To Invest In For Grandchildren. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other stocks ...